Last reviewed · How we verify
Voriconazole low dose
Voriconazole inhibits fungal lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.
Voriconazole inhibits fungal lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Invasive aspergillosis, Candidemia and other Candida infections, Esophageal candidiasis.
At a glance
| Generic name | Voriconazole low dose |
|---|---|
| Also known as | Vfend |
| Sponsor | Manjunath Prakash Pai |
| Drug class | Triazole antifungal |
| Target | Lanosterol 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Voriconazole is a triazole antifungal that selectively inhibits the cytochrome P450-dependent enzyme lanosterol 14α-demethylase (CYP51), which is essential for ergosterol biosynthesis in fungi. By blocking ergosterol production, the drug causes disruption of the fungal cell membrane integrity, leading to cell death. The low-dose formulation maintains antifungal efficacy while potentially reducing systemic exposure and associated adverse effects.
Approved indications
- Invasive aspergillosis
- Candidemia and other Candida infections
- Esophageal candidiasis
- Scedosporium and Fusarium infections
Common side effects
- Visual disturbances (blurred vision, photopsia)
- Hepatotoxicity (elevated liver enzymes)
- Rash
- Photosensitivity
- Hallucinations
- Hypokalemia
Key clinical trials
- Study of Biomarker-Based Treatment of Acute Myeloid Leukemia (PHASE1, PHASE2)
- Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant (PHASE1, PHASE2)
- Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels (PHASE1)
- Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections (PHASE2)
- Comparative Study on Tolerance and Pharmacokinetics of Voriconazole for Injection in Healthy Subjects (PHASE1)
- Three Induction Treatments on Cryptococcal Meningitis (EARLY_PHASE1)
- A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children (PHASE3)
- Pharmacokinetics of Voriconazole in Obese Subjects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Voriconazole low dose CI brief — competitive landscape report
- Voriconazole low dose updates RSS · CI watch RSS
- Manjunath Prakash Pai portfolio CI